During this pandemic year, our sense of urgency in the biomedical research community has been sharpened and tested. In oncology research, I believe that this is a time to collect that energy and use it to focus towards cures.
At Janssen Oncology, we have a singular focus: the elimination of cancer. Inspired by today’s tremendous progress and emerging new ideas, we are driven by the enormous global unmet medical need in cancer.
Unleashing the full potential of lung cancer science to help change the trajectory of this complex disease.
This timeline showcases major advances in the understanding of cancer and the development of novel therapies that are improving patient survival.
Johnson & Johnson’s integrated approach to tackling lung cancer hopes to save lives and gather lessons for other cancer types.
Instead of just treating malignancies, Janssen scientists hope to find and eliminate potentially dangerous precancerous cells or disease-driving biological conditions to intercept the disease process and prevent a cancer from ever forming.
Lung cancer is the leading cause of cancer death worldwide, but Auris is helping doctors diagnose lung cancer earlier, so treatment can happen sooner.
Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships.
A Patient Advocate’s Interview with Janssen’s Hematologic Malignancies Disease Area Leader
Margaret Yu, M.D., Vice President, Disease Area Leader, Prostate Cancer, Janssen Research & Development, shares the latest scientific strides being made in the battle against one of the most common cancers in men.
Frederic Moll, M.D., has been called “the father of robotic surgery” for good reason—his inventions have helped pave the way for improved surgical procedures for decades. His new challenge: an innovation that has the potential to diagnose and treat disease at the same time.
For National Cancer Prevention Month, we retrace the 22-year journey it took to bring a potentially life-changing treatment for an aggressive form of bladder cancer to patients who may benefit most.
The lack of diversity in clinical trials has been recognized as a major impediment to healthcare equality for decades.